Search Results - "Horowitz, N A"

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS by Gurion, R., Rozovski, U., Itchaki, G., Gafter‐Gvili, A., Leibovitch, C., Raanani, P., Szwarcwort, M., Taylor‐Abigadol, M., Dann, E., Horesh, N., Inbar, T., Tzoran, I., Lavi, N., Bar Haim, E., Cohen, H., Slouzky, I., Azoulay, T., Karmona, M., Ringelstein‐Harlev, S., Horowitz, N. A.

Get full text

P1229: RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES by Vassilakopoulos, T., Ferhanoglu, B., Horowitz, N. A., Apostolidis, J., Mellios, Z., Kaynar, L., Zektser, M., Symeonidis, A., Piperidou, A., Kalpadaki, C., Akay, O. M., Atalar, S. C., Sayyed, A., Katodritou, E., Leonidopoulou, T., Papageorgiou, S., Tadmor, T., Gutwein, O., Karakatsanis, S., Ganzel, C., Karianakis, G., Isenberg, G., Gainaru, G., Vrakidou, E., Palassopoulou, M., Ozgur, M., Siakantaris, M., Paydas, S., Tsirigotis, P., Tsirogianni, M., Hatzimichael, E., Tuglular, T. F., Chatzidimitriou, C., Liaskas, A., Lefaki, M. A., Kanellias, N., Zikos, P., Koumarianou, A., Gafter‐Gvili, A., Angelopoulou, M., Karmiris, T., Gurion, R.

Get full text

Knowing the Antibody Status may influence compliance of health care workers to COVID-19 booster dose by Magid, A, Hussein, K, Dabaja-Younis, H, Szwarcwort-Cohen, M, Almog, R, Hyams, G, Gepstein, V, Horowitz, N A, Halberthal, M, Shachor-Meyouhas, Y

Get full text

Continuous monitoring of advanced hemodynamic parameters shows early cardiovascular changes in a cohort of 492 COVID-19 hospitalized patients by Nachman, D, Eisenkraft, A, Maor, Y, Constantini, K, Goldstein, G, Levy, R, Halberthal, M, Horowitz, N A, Golan, R, Rosenberg, E, Lavon, E, Cohen, O, Shapira, G, Shomron, N, Gepner, Y

Get full text

Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations by Varon, Ben, Horowitz, Netanel A, Khatib, Hazim

“…This article provides an overview of the novel treatments focusing on the class of bispecific T cell engagers (BiTEs) for the treatment of diffuse large B-cell…”
Get full text